Efficacy and safety of semaglutide for weight management: evidence from the STEP program.
Quick Facts
What This Study Found
Semaglutide (2.4 mg once weekly) resulted in significant weight loss and improved cardiometabolic factors compared to placebo.
Key Numbers
How They Did This
The STEP program included phase 3 trials comparing semaglutide to placebo in adults with obesity, focusing on weight loss and safety.
Why This Research Matters
With obesity being a major health issue, effective treatments like semaglutide can help manage weight and reduce related health risks. Understanding its safety profile is crucial for healthcare providers.
What This Study Doesn't Tell Us
The study primarily focused on short-term outcomes, and long-term effects of semaglutide are still being evaluated.
Trust & Context
- Original Title:
- Efficacy and safety of semaglutide for weight management: evidence from the STEP program.
- Published In:
- Postgraduate medicine, 134(sup1), 5-17 (2022)
- Authors:
- Amaro, Anastassia, Sugimoto, Danny, Wharton, Sean(7)
- Database ID:
- RPEP-05984
Evidence Hierarchy
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-05984APA
Amaro, Anastassia; Sugimoto, Danny; Wharton, Sean. (2022). Efficacy and safety of semaglutide for weight management: evidence from the STEP program.. Postgraduate medicine, 134(sup1), 5-17. https://doi.org/10.1080/00325481.2022.2147326
MLA
Amaro, Anastassia, et al. "Efficacy and safety of semaglutide for weight management: evidence from the STEP program.." Postgraduate medicine, 2022. https://doi.org/10.1080/00325481.2022.2147326
RethinkPeptides
RethinkPeptides Research Database. "Efficacy and safety of semaglutide for weight management: ev..." RPEP-05984. Retrieved from https://rethinkpeptides.com/research/amaro-2022-efficacy-and-safety-of
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.